Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 8월 23

Ascendis Pharma AS

ASNDNASDAQ
Trade with Public
Trade with Public
$253.29
-1.52-0.6%
가까이에: Aug 21, 5:00 PM EST
$253.29
N/A
시간외: Aug 21, 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Ascendis Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Ascendis Pharma (ASND).

Price Target Range — 11 Quarters

Analyst Consensus — 18 Analysts

1S.Buy
17Buy
Consensus RatingBuy# Analysts18Avg. Consensus PT$287Upside to Avg. PT+13.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 19, 2026BMO CapitalDavid LebowitzInitiateOutperform$319
Aug 14, 2026TD CowenYaron WerberPT RaiseBuy$325→$341
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.
Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $275

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $256 to $275.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $280

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $275 to $280.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved